Table 1.
Activating alleles of Gαs and/or Rαs in cBioPortal cancer cohorts
| Cancer Study Type | GNASb | (%c) | GNASa,b RASb | RASb | Percent | Total Samples |
|---|---|---|---|---|---|---|
| AML | 0 | 0 | 21 | (11%) | 191 | |
| Bladder | 0 | 0 | 0 | (0%) | 131 | |
| Breast Cohort 1 | 1 | 0 | 6 | (1%) | 816 | |
| Breast Cohort 2 | 1 | 0 | 3 | (1%) | 482 | |
| Renal Clear Cell Carcinoma | 0 | 0 | 0 | (0%) | 499 | |
| Colorectal Adenocarcinoma | 1 | 0 | 91 | (43%) | 212 | |
| Head and Neck Squamous Cell | 0 | 0 | 0 | (0%) | 279 | |
| Diffuse Glioma | 0 | 0 | 8 | (1%) | 794 | |
| Lung Adenocarcinoma | 2 | (2%) | 2 | 76 | (33%) | 230 |
| Lung Squamous Cell Carcinoma | 0 | 0 | 0 | (0%) | 178 | |
| Pan-Lung Cancer | 5 | (<1%) | 3 | 232 | (20%) | 1144 |
| High Grade Serous Ovarian Cancer | 0 | 0 | 4 | (1%) | 316 | |
| Pancreatic Adenocarcinoma | 7 | (5%) | 3 | 138 | (93%) | 149 |
| Prostate Adenocarcinoma | 0 | 0 | 0 | (0%) | 333 | |
| Stomach Adenocarcinoma | 3 | (1%) | 1 | 28 | (10%) | 287 |
| Papillary Thyroid Cancer | 0 | 0 | 0 | (0%) | 507 | |
| Uterine Endometrial Carcinoma | 0 | 0 | 51 | (21%) | 240 |
aCoincidence of GNAS and KRAS activating mutations. Among the cancer cohorts from TCGA in cBioPortal [100, 101], pancreatic adenocarcinoma, pan-lung, and stomach cancers had the highest frequencies of activating alleles of Gαs in the absence of KRAS mutations
bActivating alleles of GNAS and/or KRAS
c% GNAS activating alleles with two or more occurrences in the cancer cohort